CTI BioPharma: Q4 Earnings Snapshot
SEATTLE (AP) — SEATTLE (AP) — CTI BioPharma Corp. (CTIC) on Monday reported a loss of $17.5 million in its fourth quarter.
On a per-share basis, the Seattle-based company said it had a loss of 14 cents.
The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 9 cents per share.
The biotechnology company posted revenue of $21.1 million in the period, which also missed Street forecasts. Four analysts surveyed by Zacks expected $24.9 million.
For the year, the company reported that its loss narrowed to $93 million, or 81 cents per share. Revenue was reported as $53 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CTIC at https://www.zacks.com/ap/CTIC